Cost-effectiveness of pertussis booster vaccination for preschool children in Japan. Issue 7 (11th February 2022)

• Record Type: Journal Article
• Authors: Tanaka, Motoko; Okubo, Reiko; Hoshi, Shu-Ling; Ishikawa, Nobuyuki; Kondo, Masahide
• Is Part Of: Vaccine. Volume 40:Issue 7(2022)
• Page Start: 1010
• Page End: 1018
• Publication Date: 2022-02-11
• Subjects: Pertussis -- Cost-effectiveness analysis -- Vaccine -- Preschool children -- Herd immunity; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.01.001
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Cost-effectiveness analysis of booster fifth-dose DTaP vaccination. Reflection of herd immunity from vaccinated preschool children to infants. Booster DTaP is expected to reduce pertussis cases in preschool children. Booster DTaP vaccination to preschool children would not be cost-effective in Japan. Abstract: Introduction: Japan currently recommends four doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in its routine vaccination program, but the introduction of a fifth dose is currently under consideration. An objective of the booster vaccination is to prevent severe cases of pertussis in infants through herd immunity. Thus, the aim of this analysis was to demonstrate the cost-effectiveness of a fifth-dose of the DTaP vaccine for 6-year-old children, taking herd immunity for unvaccinated infants into account. Method: An economic model analysis was conducted comparing the cost and effectiveness of the two strategies based on quality-adjusted life years (QALYs). We evaluated the incremental cost-effectiveness ratio (ICER) of the booster strategy to the no booster strategy. This model contained two sub-models: one for children aged 6 years or older and one for infants under 3 months old. Herd immunity for infants is modeled as when siblings in the same family are infected. Results: The ICER was JPY 71, 605, 491 (USD 656, 931) per QALY gained from the societal perspective, and 7.10% of incremental QALYs (0.0000934) were from a reduction in infant infection. In the sensitivity analysis, no variables moved the ICER under the threshold (JPY 5, 000, 000 per QALY gained), and the duration of pertussis disease and the incidence rate of pertussis had a significant impact on the ICER. When the disease burden of pertussis decreased, the booster strategy resulted in fewer QALYs gained and greater costs compared with the no booster strategy. Conclusion: The introduction of a DTaP booster vaccination to the routine immunization schedule can be expected to reduce the number of pertussis cases in the target population. However, our study showed that adding a booster vaccination for 6-year-old children to the schedule in Japan would not be cost-effective in terms of achieving herd immunity among unvaccinated infants.